NASDAQ:TSRX - Trius Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc. Receive TSRX News and Ratings via Email Sign-up to receive the latest news and ratings for TSRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A Current SymbolNASDAQ:TSRX Previous Symbol CUSIP89685K10 Webwww.triusrx.com Phone+1-781-8608660Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A OptionableNot Optionable Trius Therapeutics (NASDAQ:TSRX) Frequently Asked Questions What is Trius Therapeutics' stock symbol? Trius Therapeutics trades on the NASDAQ under the ticker symbol "TSRX." Has Trius Therapeutics been receiving favorable news coverage? Headlines about TSRX stock have been trending somewhat positive on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Trius Therapeutics earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the near term. How do I buy shares of Trius Therapeutics? Shares of TSRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Trius Therapeutics' official website? The official website for Trius Therapeutics is http://www.triusrx.com/. How can I contact Trius Therapeutics? Trius Therapeutics' mailing address is 65 Hayden Ave, LEXINGTON, MA 02421-7994, United States. The biopharmaceutical company can be reached via phone at +1-781-8608660. MarketBeat Community Rating for Trius Therapeutics (NASDAQ TSRX)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 117 (Vote Outperform)Underperform Votes: 61 (Vote Underperform)Total Votes: 178MarketBeat's community ratings are surveys of what our community members think about Trius Therapeutics and other stocks. Vote "Outperform" if you believe TSRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/15/2019 by MarketBeat.com StaffFeatured Article: What is the balance sheet?